Evidence map›Paper›PMID 42041183›Full record

ArticleMicrobiologyOpen2026

Synergistic Effects of IMP-1700, Ciprofloxacin, and X-Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial-Resistant Bacteria.

Ida Vang Andersen, Ane Beth Sloth, Emilie Caroline Skuladottir Bøgestad, Christian Bernard Matthijs Poulie, Anne Skovsbo Clausen, Umberto Maria Battisti, Matthias M Herth, Andreas Kjaer

Abstract read
In one paragraph

Article in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ida Vang AndersenDepartment of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-4949-8965
Ane Beth SlothDepartment of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Emilie Caroline Skuladottir BøgestadDepartment of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Christian Bernard Matthijs PoulieDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Anne Skovsbo ClausenDepartment of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Umberto Maria BattistiDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-1012-8644
Matthias M HerthDepartment of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Andreas KjaerDepartment of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Funding

Lundbeck Foundation, the Novo Nordisk Foundation, the Innovation Fund Denmark 126Lundbeck Foundation, the Novo Nordisk Foundation, the Innovation Fund Denmark 668532Lundbeck Foundation, the Novo Nordisk Foundation, the Innovation Fund Denmark 670261Lundbeck Foundation, the Novo Nordisk Foundation, the Innovation Fund Denmark NNF18SA0034956
6 · The paper itself

Abstract

IMP-1700 was developed as a compound designed to target bacterial DNA repair-associated pathways, including homologous recombination mediated by the AddAB/RecBCD system. While its antibacterial properties are well established, the potential effects on mammalian noncancerous and tumor cells under genotoxic stress remain to be elucidated. This study investigates the impact of IMP-1700 and its synergistic effect in combination with ciprofloxacin (CPX) and X-ray radiation in bacterial cultures and mammalian cell lines. In Staphylococcus aureus (S. aureus), neither IMP-1700 (5 µM) nor CPX (15 µM) as monotherapy significantly reduced bacterial growth; their combination produced a substantial reduction in bacterial counts, and IMP-1700 further enhanced killing when combined with 10 Gy X-ray irradiation, resulting in a 77% decrease, demonstrating synergistic antibacterial activity. In mammalian cells, X-ray cytotoxicity was cell-type dependent: noncancerous NIH-3T3 fibroblasts showed no significant effect, while B16.F10 melanoma cells displayed delayed sensitivity, MDA-MB-231 breast cancer cells an intermediate response, and HepG2 hepatocellular carcinoma cells marked radioresistance. IMP-1700 enhanced radiation-induced cytotoxicity across all cell lines, particularly at 72 h post-irradiation. These findings suggest that although IMP-1700 was designed to target bacterial DNA repair pathways, it can enhance sensitivity to genotoxic stress in both bacterial and mammalian systems. Further mechanistic investigation and safety evaluation are required before potential therapeutic application.

Indexed as

Anti-Bacterial AgentsCiprofloxacinStaphylococcus aureusAnimalsCell LineCell SurvivalDrug Resistance, BacterialHumansMiceMicrobial Sensitivity TestsX-RaysAnti-Bacterial AgentsCiprofloxacinB16.F10ciprofloxacinHepG2IMP‐1700MDA.MB.231NIH‐3T3S. aureusX‐ray

Identifiers

PMID42041183
PMCPMC13112599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.